Unlike the first half of this year, many pharmaceutical-themed funds completed the transition from “running with you” to “leading the way” in the third quarter, achieving a “breakthrough in performance.” As of the press release, the net worth growth rate of many pharmaceutical-themed funds, such as the Hong Kong Stock Medical ETF Yongying, the China-Europe Pharmaceutical Biotech Hybrid Launch, and the Southern Hong Kong Pharmaceutical Industry Hybrid Launch, had the highest net worth growth rates. Looking ahead to the future market, the manager of the Nanfanggang Pharmaceutical Industry Hybrid Fund said that he will continue to be optimistic about innovative drugs and medium- to long-term opportunities in the innovative drug industry chain. Through bottom-up research, the portfolio will continue to find companies with clear industry trends, verifiable fundamentals, and reasonable room for return in valuation, and dynamically rebalance the direction of innovative drugs, CXO, and emerging technologies.

Unlike the first half of this year, many pharmaceutical-themed funds completed the transition from “running with you” to “leading the way” in the third quarter, achieving a “breakthrough in performance.” As of the press release, the net worth growth rate of many pharmaceutical-themed funds, such as the Hong Kong Stock Medical ETF Yongying, the China-Europe Pharmaceutical Biotech Hybrid Launch, and the Southern Hong Kong Pharmaceutical Industry Hybrid Launch, had the highest net worth growth rates. Looking ahead to the future market, the manager of the Nanfanggang Pharmaceutical Industry Hybrid Fund said that he will continue to be optimistic about innovative drugs and medium- to long-term opportunities in the innovative drug industry chain. Through bottom-up research, the portfolio will continue to find companies with clear industry trends, verifiable fundamentals, and reasonable room for return in valuation, and dynamically rebalance the direction of innovative drugs, CXO, and emerging technologies.